...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience.
【24h】

E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience.

机译：根据国际生殖细胞癌合作组织（IGCCCG）的分类，E400P在晚期精原细胞瘤中预后良好：西班牙生殖细胞癌研究组的经验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To evaluate the efficacy and toxicity of primary chemotherapy with the schedule E400P in the treatment of patients with early stage II (IIa and IIb) and advanced seminoma of good prognosis according to the international classification (IGCCCG). PATIENTS AND METHODS: Sixty-four patients were included. E400P consisted of cisplatin 25 mg/m2/day and etoposide 100 mg/m2/day for four days, every three weeks. Royal Marsden stages were IIab: 53% and IIc-IV: 47%. Twenty-three percent had high BHCG levels, twenty-seven percent had LDH > 2 x N. Sixty-two patients were of good prognosis according to the Medical Research Council classification. RESULTS: Response rate was 98% (69% complete remission, 29% residual disease). After a median follow-up of 34 months, treatment failure was seen in 7 patients (11%). Neutropenia (32%) was the most relevant grade 3-4 toxicity. Other important grade 3-4 side effects were found in less than 5%. Three-year time to treatment failure (TTF) was 89% (95% confidence intervals (CI): 80%-97%) for all patients, 91% (95% CI: 80%-99%) for stages IIa-b, and 87% (95% CI: 74%-99%) for stages IIc-IV. Three-year overall survival (OS) was 97% (95% CI: 93%-99%) for all patients and 95% (95% CI: 85%-99%) for stages IIa-b. CONCLUSIONS: E400P was a very active and safe regimen in good-prognosis advanced seminoma, with low toxicity rates. Definitive comparisons of this regimen with radiotherapy in stages IIa-b or with the more standard E500P or BEP, could be of interest.
机译：目的：根据国际分类法（IGCCCG），评估E400P方案治疗初治II期早期（IIa和IIb）和晚期精原细胞瘤的疗效和毒性。患者与方法：纳入64例患者。 E400P每隔三周包含25天的顺铂和100 mg / m2 /天的依托泊苷。 Royal Marsden阶段分别为IIab：53％和IIc-IV：47％。 23％的人的BHCG水平高，27％的人的LDH> 2 xN。根据医学研究理事会的分类，有62例患者的预后良好。结果：缓解率为98％（完全缓解69％，残留疾病29％）。中位随访34个月后，有7例患者（11％）出现治疗失败。中性粒细胞减少症（32％）是最相关的3-4级毒性。发现其他重要的3-4级副作用小于5％。所有患者的三年治疗失败时间（TTF）为89％（95％置信区间（CI）：80％-97％），IIa-b期为91％（95％CI：80％-99％） ，而对于IIc-IV期则为87％（95％CI：74％-99％）。所有患者的三年总体生存率（OS）为97％（95％CI：93％-99％），IIa-b期为95％（95％CI：85％-99％）。结论：E400P是一种预后良好的晚期精原细胞瘤，是一种非常有效和安全的方案，毒性低。可能需要对该方案与IIa-b期放疗或更标准的E500P或BEP进行明确的比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号